Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia
- Author
- ANDRIOLE, Gerald1 ; BRUCHOVSKY, Nicholas2 ; CHUNG, Leland W. K3 ; MATSUMOTO, Alvin M4 ; RITTMASTER, Roger5 ; ROEHRBORN, Claus6 ; RUSSELL, David6 ; TINDALL, Donald7
[1] Washington University in St. Louis, St. Louis, Missouri, United States
[2] British Columbia Cancer Agency, Vancouver, British Columbia, Canada
[3] Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
[4] University of Washington School of Medicine and Geriatric Research, Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States
[5] GlaxoSmithKline, Research Triangle Park, North Carolina, United States
[6] University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
[7] Mayo Clinic College of Medicine, Rochester, Minnesota, United States - Source
The Journal of urology. 2004, Vol 172, Num 4, pp 1399-1403, 5 p ; 1 ; ref : 20 ref
- CODEN
- JOURAA
- ISSN
- 0022-5347
- Scientific domain
- Urology, nephrology
- Publisher
- Lippincott Williams & Wilkins, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- GG 745 dihydrotestosterone finasteride prostate prostatic hyperplasia
- Keyword (fr)
- Anticancéreux Dihydrotestostérone Finastéride Hyperplasie Inhibiteur Reductase Traitement Urologie Adénome prostate Néphrologie Antiandrogène Antihormone Appareil génital mâle pathologie Appareil urinaire pathologie Appareil urogénital Azastéroïde Enzyme Oxidoreductases Prostate pathologie Tumeur bénigne
- Keyword (en)
- Antineoplastic agent Dihydrotestosterone Finasteride Hyperplasia Inhibitor Reductase Treatment Urology Benign prostatic hyperplasia Nephrology Antiandrogen Antihormone Male genital diseases Urinary system disease Urogenital system Azasteroid Enzyme Oxidoreductases Prostate disease Benign neoplasm
- Keyword (es)
- Anticanceroso Dihidrotestosterona Finasterida Hiperplasia Inhibidor Reductase Tratamiento Urología Hiperplasia prostática benigna Nefrología Antiandrógeno Antihormona Aparato genital macho patología Aparato urinario patología Aparato urogenital Azasteroide Enzima Oxidoreductases Prostata patología Tumor benigno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B14 Nephrology. Urinary tract diseases / 002B14D Tumors of the urinary system / 002B14D02 Urinary tract. Prostate gland
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B20 Gynecology. Andrology. Obstetrics / 002B20B Male genital diseases / 002B20B02 Tumors
- Discipline
- Gynecology. Andrology. Obstetrics Nephrology. Urinary tract diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16140491
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1097/01.ju.0000139539.94828.29 
https://dx.doi.org/10.1097/01.ju.0000139539.94828.29
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1097\/01.ju.0000139539.94828.29\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:3:\"172\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1399\";s:8:\"\u0000*\u0000epage\";s:4:\"1403\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDRIOLE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gerald\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:20:\"BRUCHOVSKY, Nicholas\";i:1;s:18:\"CHUNG, Leland W. K\";i:2;s:18:\"MATSUMOTO, Alvin M\";i:3;s:17:\"RITTMASTER, Roger\";i:4;s:16:\"ROEHRBORN, Claus\";i:5;s:14:\"RUSSELL, David\";i:6;s:15:\"TINDALL, Donald\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1097\/01.ju.0000139539.94828.29\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:3:\"172\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1399\";s:8:\"\u0000*\u0000epage\";s:4:\"1403\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDRIOLE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gerald\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:20:\"BRUCHOVSKY, Nicholas\";i:1;s:18:\"CHUNG, Leland W. K\";i:2;s:18:\"MATSUMOTO, Alvin M\";i:3;s:17:\"RITTMASTER, Roger\";i:4;s:16:\"ROEHRBORN, Claus\";i:5;s:14:\"RUSSELL, David\";i:6;s:15:\"TINDALL, Donald\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:33:\"10.1097\/01.ju.0000139539.94828.29\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1097\/01.ju.0000139539.94828.29\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:3:\"172\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1399\";s:8:\"\u0000*\u0000epage\";s:4:\"1403\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDRIOLE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gerald\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:20:\"BRUCHOVSKY, Nicholas\";i:1;s:18:\"CHUNG, Leland W. K\";i:2;s:18:\"MATSUMOTO, Alvin M\";i:3;s:17:\"RITTMASTER, Roger\";i:4;s:16:\"ROEHRBORN, Claus\";i:5;s:14:\"RUSSELL, David\";i:6;s:15:\"TINDALL, Donald\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1097\/01.ju.0000139539.94828.29\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:3:\"172\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1399\";s:8:\"\u0000*\u0000epage\";s:4:\"1403\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDRIOLE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gerald\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:20:\"BRUCHOVSKY, Nicholas\";i:1;s:18:\"CHUNG, Leland W. K\";i:2;s:18:\"MATSUMOTO, Alvin M\";i:3;s:17:\"RITTMASTER, Roger\";i:4;s:16:\"ROEHRBORN, Claus\";i:5;s:14:\"RUSSELL, David\";i:6;s:15:\"TINDALL, Donald\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:33:\"10.1097\/01.ju.0000139539.94828.29\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:3:\"172\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1399\";s:8:\"\u0000*\u0000epage\";s:4:\"1403\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"ANDRIOLE\";s:10:\"\u0000*\u0000aufirst\";s:6:\"Gerald\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:20:\"BRUCHOVSKY, Nicholas\";i:1;s:18:\"CHUNG, Leland W. K\";i:2;s:18:\"MATSUMOTO, Alvin M\";i:3;s:17:\"RITTMASTER, Roger\";i:4;s:16:\"ROEHRBORN, Claus\";i:5;s:14:\"RUSSELL, David\";i:6;s:15:\"TINDALL, Donald\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"1\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:140:\"Dihydrotestosterone and the prostate: The scientific rationale for 5\u03b1-reductase inhibitors in the treatment of benign prostatic hyperplasia\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"5\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
